Pharmacological treatment for patients with borderline personality disorder: Practice and study results;Pharmakotherapie der Borderline-Störung: Praxis und Studienlage

Fortschritte der Neurologie Psychiatrie

Volumn 81, Issue 8, 2013, Pages 437-443

  Schwerthoffer D ^a   Bauml J ^a   Rentrop, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

borderline personality disorder (BPD); off label use; pharmacological treatment for BPD

Indexed keywords

ARTICLE; BORDERLINE STATE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BORDERLINE PERSONALITY DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; FATTY ACIDS, OMEGA-3; HUMANS; MENTAL DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84881512419     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0033-1335385     Document Type: Article

References (49)

1. Mercer D., Douglass A. B., Links P. S. Meta-Analyses of Mood-Stabilizers, Antidepressants and Antipsychotics in the treatment of Borderline Personality Disorder: Effectiveness for Depression and Anger symptoms. J Personality Disord: 2009; 23 156 174
2. Lieb K., Völlm B., Rücker G. et al. Pharmacotherapy for Borderline Personality Disorder: Cochrane systematic review of randomised trials. Brit J Psych: 2010; 196 4 12
3. Lieb K., Zanarini M. C., Schmahl C. et al. Borderline Personality Disorder. Lancet: 2004; 364 453 461 (Pubitemid 39036894)
4. Normann C., van Calcer D., Voderholzer U. et al. Off-label-Indikationen in der Psychopharmakotherapie. Nervenarzt: 2003; 74 815 823
5. Rentrop M., Reicherzer M., Bäuml J. Psychoedukation Borderline Störung. 1 Aufl. München Elsevier Urban&Fischer: 2006
6. Benkert O., Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. 5 Aufl. Springer Verlag Heidelberg: 2005
7. Rentrop M., Martius P., Bäuml J. et al. Patients with borderline personality disorder not participating in an RCT: are they different? Psychopathology: 2010; 43 369 372
8. Montgomery D., Roy D., Montgomery S. et al. Mianserin in the prophylaxis of suicidal behaviour: a double-blind placebo controlled trial. In Proceedings of the 10th International Congress of Suicide Prevention and Crisis Interv. Pergamon: 1981; 786 790
9. Soloff P. H., George A., Nathan S. et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol: 1989; 9 238 246 (Pubitemid 19198957)
10. Soloff P. H., Cornelius J., George A. et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry: 1993; 50 377 385 (Pubitemid 23143127)
11. Salzmann C., Wolfson A. N., Schatzberger A. et al. Effect of Fluoxetin on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol: 1995; 15 23 29
12. Rinne T., van der Brink W., Wouter L. et al. SSRI treatment of borderline personality disorder: a randomised, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry: 2002; 159 2048 2054 (Pubitemid 35423864)
13. Simson Simpson EB, Yen S., Costello E. et al. Combined dialectical behavior therapy and fluoxetin in a treatment of borderline personality disorder. J Clin Psychiatry: 2004; 65 379 385
14. Zanarini M. C., Frankenburg F. R., Parachini E. A. A preliminary, randomized trial of fluoxetin, olanazapin, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry: 2004; 65 903 907
15. Herpertz S. C., Zanarini M., Schulz C. S. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment for Personality Disorders. World J Bio Psychiatry: 2007; 8 04 212 244 (Pubitemid 350018476)
16. Knappich M., Rentrop M. Pharmacotherapy in the treatment of Patients with Borderline Personality Disorder. Results of a survey among psychiatrists in private practices. European Psych [under reviewing]
17. Aigner M., Treasure J., Kaye W. et al. WFSBP Task Force On Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry: 2011; 12 400 443
18. Abraham P. F., Calabrese J. R. Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord: 2008; 111 21 30
19. Montgomery S. A., Montgomery D. B., Janianthi R. S. et al. Maintenance therapy in repeat suicidal behaviour: a placebo controlled trial. In Procedings of the 10th International Congress of Suicide Prevention and Crisis Intervention. International Association for Suicide Prevention: 1979; 227 229
20. Goldberg S. C., Schulz S. C., Schulz P. M. et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs. placebo. Arch Gen Psychiatry: 1986; 43 680 686 (Pubitemid 16094180)
21. Soloff P. H., George A., Nathan S. et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol: 1989; 9 238 246 (Pubitemid 19198957)
22. Soloff P. H., Cornelius J., George A. et al. Efficacy of phenezine and haloperidol in borderline personality disorder. Arch Gen Psychiatry: 1993; 50 377 385 (Pubitemid 23143127)
23. Zanarini M. C., Frankenburg F. R. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry: 2001; 62 849 854 (Pubitemid 33131170)
24. Bogenschutz M. P., Nurnberg H. G. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry: 2004; 65 104 109
25. Zanarini M. C., Frankenburg F. R., Parachini E. A. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry: 2004; 65 903 907
26. Soler J., Pascual J. C., Campins J. et al. Double-blind, placebo-controlled study of dialectical behaviour therapy plus olanzapine for borderline personality disorder. Am J Psychiatry: 2005; 162 1221 1224 (Pubitemid 40770712)
27. Nickel M. K., Muehlbacher M., Nickel C. et al. Aripiprazol in the treatment of patients with borderline personality disorder: a double blind, placebo controlled study. J Clin Psychiatry: 2006; 1663 833 838 (Pubitemid 44464531)
28. Schulz S. C., Zanarini M. C., Bateman A. et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12week randomised double-blind placebo-controlled study. Br J Psychiatry: 2008; 193 485 492
29. Linehan M. M., McDavid J. D., Brown M. Z. et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry: 2008; 69 999 1005 (Pubitemid 351944956)
30. Pascual J. C., Soler J., Puigdemont D. et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry: 2008; 69 603 608 (Pubitemid 351792335)
31. Feurino L., Kenneth Silk KR. State of the Art in the Pharmacologic Treatment of Borderline Personality Disorder. Curr Psychiatry Rep: 2011; 13 69 75
32. De la Fuente J. M., Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol: 1994; 4 479 486
33. Hollaender E., Allen A., Lopez R. P. et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry: 2001; 62 199 203 (Pubitemid 32270095)
34. Frankenburg F. R., Zanarini M. C. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double blind placebo-controlled pilot study. J Clin Psychiatry: 2002; 63 442 446 (Pubitemid 34507223)
35. Nickel M. K., Nickel C., Mitterlehner F. O. et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry: 2004; 65 1515 1519
36. Nickel M. K., Nickel C., Kaplan P. et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry: 2005; 57 495 499 (Pubitemid 40311984)
37. Tritt K., Nickel C., Lahmann C. et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol: 2005; 19 287 291 (Pubitemid 40694947)
38. Loew T. H., Nickel M. K., Muehlbacher M. et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharm: 2006; 26 61 66 (Pubitemid 43167093)
39. McGlashan T. H., Grilo C. M., Skodol A. E. et al. The collaborative longitudinal personality disorders study: baseline Axis I/II ans II/II diagnostic co-occurrence. Acta Psychiatr Scand: 2000; 102 256 264
40. National Collaborating Centre for Mental Health Borderline Personality Disorder: The NICE GUIDELINE on Treatment and Management. National Clinical Practice Guideline No. 78. British Psychological Society & Royal College of Psychiatrists: 2009
41. Hallahan B., Hibbeln J. R., Davis J. M. et al. Omega-3 fatty acid supplementation in patients with recurrent self-harm: single-centre double-blind randomised controlled trial. Br J Psychiatry: 2007; 190 118 122
42. Zanarini M. C., Frankenburg F. R. Omega-3 fatty acid treatment of women with borderline personality disorder: a double blind, placebo-controlled pilot study. Am J Psychiatry: 2003; 160 167 169 (Pubitemid 36042442)
43. Ziegenhorn A. A., Roepke S., Schommer N. C. et al. Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharma: 2009; 29 170 173
44. Schmahl C., Kleindienst N., Limberger M. et al. Evaluation of naltrexone in dissociative symptoms in borderline personality disorder. Int Clin Psychopharmacol: 2012; 27 61 68
45. Speranza M., Revah-Levy A., Cortese S. et al. ADHD in adolescents with borderline personality disorder. BMC Psychiatry: 2011; 24 158 161
46. Philipsen A., Limberger M. F., Lieb K. et al. Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. Br J Psychiatry: 2008; 192 118 123 (Pubitemid 351269645)
47. Golubchik P., Sever J., Zalsman G. et al. Methylphenidate in the treatment of female adolescents with cooccurence of attention- deficithyperactivity disorder and borderline personality disorder: a preliminary open label trial. Int Clin Psychopharmacol: 2008; 23 228 231
48. American Psychiatric Association Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry: 2001; 158 10 1 52
49. Tyrer P, Silk KR. A comparison of UK and US guidelines for drug treatment in borderline personality disorder. Int Rev Psychiatry 2011; 23: 388-394